ARCT compared with TXG: revenue, margins and what each company keeps, and the suppliers and customers both name

ARCTArcturus Therapeutics Holdings Inc.

Mkt capRevenueRevenue

TXG10x Genomics, Inc.

Mkt capRevenueRevenue

Compare

ARCTArcturus Therapeutics Holdings Inc.

TXG10x Genomics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ARCT 3

—Biomedical Advanced Research and Development Authority (BARDA)unlistedcustomer

—CSL Seqirusunlistedcustomer

—Meiji Seika Pharmaunlistedcustomer

Shared 0

No shared counterparties.

Only TXG 4

BRKRBrukercustomer

—President and Fellows of Harvard Universityunlistedsupplier

—The Board of Trustees of the Leland Stanford Junior Universityunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Vizgen

unlistedcustomer

ARCTArcturus Therapeutics Holdings Inc.

10.36▲+10.67%· post 10.36

Mkt cap$269.8MRevenue$18MQ3 FY26Revenue$82MFY25

TXG10x Genomics, Inc.

59.06▲+1.72%· post 59.44

ClosedNov 6 '26

Mkt cap$7.6BRevenue$151MQ3 FY26Revenue$643MFY25

Compare

ClosedNov 6 '26

ARCTArcturus Therapeutics Holdings Inc.

TXG10x Genomics, Inc.

10.36▲+10.67%post 10.36

Price

59.06▲+1.72%post 59.44

$269.8M

Mkt cap

$7.6B

Q3 FY26$18M

Revenue

$151MQ3 FY26

FY25$82M

Revenue

$643MFY25

ARCT10.36▲+10.67%vsTXG59.06▲+1.72%ClosedNov 6 '26